BioGend Therapeutics (6733) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 博晟生醫

BioGend Therapeutics (6733) reported revenue of NT$21.4 million for Oct 2026, +24.8% year on year and +0.0% from the previous month. Revenue for Jan–Oct 2026 was NT$196.1 million (+9.6% year on year).

Year-on-year revenue growth: 3 months in a row. →

In Oct 2026, it ranked No. 123 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$17.3 million24/10Nov 2024 NT$14 millionDec 2024 NT$20.1 millionJan 2025 NT$17.3 millionFeb 2025 NT$15.1 million25/02Mar 2025 NT$15 millionApr 2025 NT$19.4 millionMay 2025 NT$18.7 millionJun 2025 NT$14.6 million25/06Jul 2025 NT$24.5 millionAug 2025 NT$17.6 millionSep 2025 NT$19.5 millionOct 2025 NT$17.1 million25/10Nov 2025 NT$20.1 millionDec 2025 NT$23.2 millionJan 2026 NT$23 millionFeb 2026 NT$15.3 million26/02Mar 2026 NT$16.6 millionApr 2026 NT$19.6 millionMay 2026 NT$16 millionJun 2026 NT$23.8 million26/06Jul 2026 NT$19.7 millionAug 2026 NT$19.3 millionSep 2026 NT$21.4 millionOct 2026 NT$21.4 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$21.4 million+24.8%+0.0%
Sep 2026NT$21.4 million+9.5%+10.9%
Aug 2026NT$19.3 million+9.3%-2.2%
Jul 2026NT$19.7 million-19.5%-17.2%
Jun 2026NT$23.8 million+63.6%+48.7%
May 2026NT$16 million-14.5%-18.3%
Apr 2026NT$19.6 million+0.9%+18.0%
Mar 2026NT$16.6 million+10.4%+8.5%
Feb 2026NT$15.3 million+1.4%-33.5%
Jan 2026NT$23 million+32.9%-0.8%
Dec 2025NT$23.2 million+15.5%+15.2%
Nov 2025NT$20.1 million+43.8%+17.5%
Oct 2025NT$17.1 million-0.8%-12.3%
Sep 2025NT$19.5 million+55.8%+10.8%
Aug 2025NT$17.6 million+9.7%-28.0%
Jul 2025NT$24.5 million+55.4%+68.2%
Jun 2025NT$14.6 million+59.7%-22.3%
May 2025NT$18.7 million+44.1%-3.5%
Apr 2025NT$19.4 million+28.1%+29.1%
Mar 2025NT$15 million-1.9%-0.3%
Feb 2025NT$15.1 million+79.6%-12.9%
Jan 2025NT$17.3 million+49.1%-13.7%
Dec 2024NT$20.1 million+82.5%+43.4%
Nov 2024NT$14 million+51.7%-18.9%
Oct 2024NT$17.3 million-3.5%+37.8%

Jan–Oct 2026 cumulative: NT$196.1 million (+9.6% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: BioGend Therapeutics vs PEC / BioGend Therapeutics vs Lotus Pharm / BioGend Therapeutics vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

係銷售醫療器材及抗生素之收入。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16